Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Ovarian Cancer clinical trials
Every US clinical trial registered for Ovarian Cancer — phase mix, recruiting status, and the sponsors running them, straight from the NIH ClinicalTrials.gov registry.
337 US clinical trials · 147 currently recruiting
The research picture
Ovarian Cancer has 337 registered US clinical trials, 147 of them open to new participants right now — about 44% of the total.
- 147
- recruiting participants now
- 44%
- of trials open to enrollment
- 28
- in Phase 3–4 (later-stage)
- 31
- top sponsor: Memorial Sloan Kettering Cancer Center
Counts reflect the public ClinicalTrials.gov registry as last mirrored by PlainTrial. Status and phase are reported by each study's sponsor. This is reference information, not medical advice.
Active & Recent Trials
Transvaginal Ultrasonography as a Screening Method for Ovarian Cancer
John R van Nagell
NCT04473833
Avera Cancer Sequencing and Analytics Protocol (ASAP)
Avera McKennan Hospital & University Health Center
NCT05142033
Sample Collection for Ongoing Research and Product Evaluation Study
Natera
NCT07318051
Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women
M.D. Anderson Cancer Center
NCT00539162
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
Northwestern University
NCT00005095
Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples
Stanford University
NCT01034033
Evaluating an Evidence-Based Family History Screening Program Adapted to Increase Reach and Uptake of Screening for BRCA-Associated Cancers in Rural Public Health Clinics
Emory University
NCT06760507
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
Mayo Clinic
NCT05051722
TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
University Medical Center Nijmegen
NCT04294927
UNTOLD Ovarian Cancer Unmet Needs Survey
Masonic Cancer Center, University of Minnesota
NCT07070726
The DETECT Study: Discovery and Evaluation of Testing for Endometrial and Ovarian Cancer in Tampons
University of Alabama at Birmingham
NCT03538665
EXoPERT EMERALD Clinical Study
EXoPERT
NCT07186296
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
National Cancer Institute (NCI)
NCT01441089
Video Education With Result Dependent dIsclosure
Dana-Farber Cancer Institute
NCT05225428
Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics.
M.D. Anderson Cancer Center
NCT05649072
Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)
University of California, San Francis
NCT05056077
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Merck Sharp & Dohme
NCT07318558
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Merck Sharp & Dohme
NCT06824467
Comprehensive Outcomes for After Cancer Health
Pack Health
NCT05349227
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
Regeneron Pharmaceuticals
NCT04590326
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Daiichi Sankyo
NCT06819007
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
The Netherlands Cancer Institute
NCT03772028
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
Genmab
NCT07225270
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
AbbVie
NCT05445778
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
AstraZeneca
NCT05797168
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
Imunon
NCT06915025
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
Eli Lilly and Company
NCT06238479
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
Memorial Sloan Kettering Cancer Center
NCT05053230
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
SystImmune
NCT05983432
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Incyte Corporation
NCT07214779
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
AstraZeneca
NCT05123482
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
AstraZeneca
NCT05489211
Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients
Memorial Sloan Kettering Cancer Center
NCT04751435
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Artios Pharma
NCT04657068
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Eli Lilly and Company
NCT06465069
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Conjupro Biotherapeutics
NCT07424547
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
National Cancer Institute (NCI)
NCT06503146
A Study of XMT-1660 in Participants With Solid Tumors
Mersana Therapeutics
NCT05377996
A Study of Intra-operative Imaging in Women With Ovarian Cancer
Memorial Sloan Kettering Cancer Center
NCT04878094
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PMV Pharmaceuticals
NCT04585750
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
National Cancer Institute (NCI)
NCT03412877
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Xencor
NCT06276491
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
SystImmune
NCT06293898
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Corcept Therapeutics
NCT06906341
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
OnCusp Therapeutics
NCT06234423
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
BeiGene
NCT06257264
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Tubulis
NCT06303505
The SENTRY Study: Testing Whether Changes in Platelet RNA Enhance the Early Diagnosis of Ovarian Cancer
University of Utah
NCT06665945
REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors
Dana-Farber Cancer Institute
NCT06710548
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Whitehawk Therapeutics
NCT07444814
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
MOMA Therapeutics
NCT06545942
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Regeneron Pharmaceuticals
NCT06787612
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
IDEAYA Biosciences
NCT05787587
Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
National Cancer Institute (NCI)
NCT06253520
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
AbbVie
NCT07278336
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
NiKang Therapeutics
NCT07029399
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Terremoto Biosciences
NCT07109726
Trial of Exercise and Lifestyle for Women With Ovarian and Endometrial Cancer
Yale University
NCT05761561
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
A2 Biotherapeutics
NCT04981119
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Jazz Pharmaceuticals
NCT06695845
RESOLVE: Abemaciclib + Letrozole +/- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer
Dana-Farber Cancer Institute
NCT03675893
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
BioInvent International AB
NCT04752826
Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
NX Development
NCT05804370
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Incyte Corporation
NCT07023627
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
NiKang Therapeutics
NCT06586957
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Normunity AccelCo
NCT07182149
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Incyclix Bio
NCT05735080
A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
Qurgen
NCT05989724
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
NextCure
NCT06774963
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
National Cancer Institute (NCI)
NCT02830724
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
AtlasMedx, Incorporated
NCT04503265
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
858 Therapeutics
NCT06395519
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
Oncoinvent Solutions AS
NCT06504147
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Fate Therapeutics
NCT07216105
Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovarian Cancer
Dana-Farber Cancer Institute
NCT06543537
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Perspective Therapeutics
NCT06710756
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
AstraZeneca
NCT06973161
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Nammi Therapeutics
NCT06582017
Using Aspirin to Improve Immunological Features of Ovarian Tumors
H. Lee Moffitt Cancer Center and Research Institute
NCT05080946
Laboratory Study of Cancer & Immune Cells in Ascites Fluid of Ovarian Cancer Patients to Test Alternative Therapies
New Mexico Cancer Research Alliance
NCT03943316
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
Apollo Therapeutics
NCT06399757
Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study
M.D. Anderson Cancer Center
NCT05287451
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Dren Bio
NCT06999187
AOH1996 for the Treatment of Refractory Solid Tumors
City of Hope Medical Center
NCT05227326
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
Accent Therapeutics
NCT06799065
A Study of Isoquercetin in People With Ovarian Cancer
Memorial Sloan Kettering Cancer Center
NCT07303894
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Clasp Therapeutics
NCT06778863
TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors
Portage Biotech
NCT04969315
ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK
Michael McHale
NCT03287271
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
TORL Biotherapeutics
NCT05103683
Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy
University of California, Davis
NCT06268665
Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery
Memorial Sloan Kettering Cancer Center
NCT06290193
IDOV-Immune for Advanced Solid Tumors
ViroMissile
NCT06910657
ASk Questions in GYnecologic Oncology (ASQ-GYO)
Ira Winer
NCT06339827
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
University of Alabama at Birmingham
NCT04606914
Study Evaluating Safety, Tolerability, and Metabolism of Niraparib
University of Miami
NCT06412120
Hugo™ Robotic-Assisted Surgery (RAS) System in Gynecological Subjects (Embrace Gynecology)
Medtronic - MITG
NCT07120945
Spanish Decision Tool for Ovarian Cancer Maintenance Therapy
M.D. Anderson Cancer Center
NCT06036810
SLV-154 Treatment of Metastatic Solid Tumors
Solve Therapeutics
NCT06771219
Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies
University of California, Irvine
NCT07064018
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 142 |
| Phase 2 | 87 |
| Phase 3 | 25 |
| Phase 4 | 3 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the Ovarian Cancer Trial Landscape
ClinicalTrials.gov lists 337 US studies indexed under Ovarian Cancer, and 147 of those are currently open to recruitment — roughly 44% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
The phase distribution for Ovarian Cancer shows 28 late-stage studies (Phase 3 and Phase 4 combined) alongside 229 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
Top sponsor activity for Ovarian Cancer is led by Memorial Sloan Kettering Cancer Center with 31 indexed trials, alongside 9 other organizations in the top contributor list. The list on this page surfaces up to 100 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for Ovarian Cancer?
PlainTrial tracks 337 US clinical trials for Ovarian Cancer, of which 147 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Ovarian Cancer?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.